Trials / Recruiting
RecruitingNCT05528341
NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors
Clinical Investigation of NKG2D-CAR-NK92 Chimeric Antigen Receptor Modified NK92 Cells in the Treatment of Relapsed/Refractory Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Henan Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical investigation is to evaluate the safety and effects of NKG2D-CAR-NK92 infusions in the treatment of relapsed/refractory solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NKG2D-CAR-NK92 cells | NKG2D-CAR-NK92 cells will be administered intravenously over 1h. The starting dose of NKG2D-CAR-NK92 cells will be 0.5×10\^6-2×10\^6/kg, twice a week. The first evaluation of the efficacy after 3 weeks of treatment. |
Timeline
- Start date
- 2023-01-26
- Primary completion
- 2026-04-01
- Completion
- 2026-04-01
- First posted
- 2022-09-06
- Last updated
- 2025-04-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05528341. Inclusion in this directory is not an endorsement.